- Home
- ANEB vs PMN Comparison
ANEB vs PMN Comparison
Compare ANEB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- PMN
- Stock Information
- Founded
- ANEB 2020
- PMN 2004
- Country
- ANEB United States
- PMN Canada
- Employees
- ANEB N/A
- PMN N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- ANEB Health Care
- PMN Health Care
- Exchange
- ANEB Nasdaq
- PMN Nasdaq
- Market Cap
- ANEB 111.8M
- PMN 23.5M
- IPO Year
- ANEB 2021
- PMN N/A
- Fundamental
- Price
- ANEB $2.75
- PMN $0.44
- Analyst Decision
- ANEB Buy
- PMN Strong Buy
- Analyst Count
- ANEB 2
- PMN 3
- Target Price
- ANEB $8.00
- PMN $4.33
- AVG Volume (30 Days)
- ANEB 25.7K
- PMN 872.4K
- Earning Date
- ANEB 11-12-2025
- PMN 11-13-2025
- Dividend Yield
- ANEB N/A
- PMN N/A
- EPS Growth
- ANEB N/A
- PMN N/A
- EPS
- ANEB N/A
- PMN N/A
- Revenue
- ANEB N/A
- PMN N/A
- Revenue This Year
- ANEB N/A
- PMN N/A
- Revenue Next Year
- ANEB N/A
- PMN N/A
- P/E Ratio
- ANEB N/A
- PMN N/A
- Revenue Growth
- ANEB N/A
- PMN N/A
- 52 Week Low
- ANEB $0.80
- PMN $0.38
- 52 Week High
- ANEB $3.42
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- ANEB 62.06
- PMN 43.08
- Support Level
- ANEB $2.50
- PMN $0.41
- Resistance Level
- ANEB $2.76
- PMN $0.46
- Average True Range (ATR)
- ANEB 0.13
- PMN 0.04
- MACD
- ANEB 0.04
- PMN -0.01
- Stochastic Oscillator
- ANEB 79.03
- PMN 10.04
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.